Nanoparticles for Cancer Diagnosis and Treatment

A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Cancer Therapies".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 3756

Special Issue Editor


E-Mail Website
Guest Editor
Center of Nanomedicine, Brigham and Women’s Hospital, Boston, MA, USA
Interests: lipid nanoparticles; cancer immunotherapy; targeted delivery; polymeric nanoparticles

Special Issue Information

Dear Colleagues,

Cancer is the leading cause of death worldwide. Research on early diagnosis will help cure the disease at earlier stages. Chemotherapy is a frequently used treatment option for cancer, but this results in unwanted side effects. Nanotechnology-based targeted delivery of chemotherapeutic agents to cancer cells will ensure better therapeutic outcomes and minimize unwanted side effects. Lipid nanoparticles have been proven to be instrumental in gene therapy for the treatment of cancer and other infectious diseases. Immunotherapy for cancer is another attractive approach to achieve better therapeutic outcomes. In this Special Issue, we will focus on nanoparticle-based strategies for the diagnosis and treatment of cancer.

Dr. Muhammad Muzamil Khan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lipid nanoparticles
  • tumor targeting
  • cancer diagnostics
  • cancer immunotherapy
  • gene therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 1983 KiB  
Review
Iron Oxide Nanoparticles: Parameters for Optimized Photoconversion Efficiency in Synergistic Cancer Treatment
by Tsenka Grancharova, Plamen Zagorchev and Bissera Pilicheva
J. Funct. Biomater. 2024, 15(8), 207; https://doi.org/10.3390/jfb15080207 - 25 Jul 2024
Cited by 11 | Viewed by 3394
Abstract
Photothermal therapy (PTT) can overcome cancer treatment resistance by enhancing the cell membrane permeability, facilitating drug accumulation, and promoting drug release within the tumor tissue. Iron oxide nanoparticles (IONPs) have emerged as effective agents for PTT due to their unique properties and biocompatibility. [...] Read more.
Photothermal therapy (PTT) can overcome cancer treatment resistance by enhancing the cell membrane permeability, facilitating drug accumulation, and promoting drug release within the tumor tissue. Iron oxide nanoparticles (IONPs) have emerged as effective agents for PTT due to their unique properties and biocompatibility. Approved for the treatment of anemia, as MRI contrast agents, and as magnetic hyperthermia mediators, IONPs also offer excellent light-to-heat conversion and can be manipulated using external magnetic fields for targeted accumulation in specific tissue. Optimizing parameters such as the laser wavelength, power density, shape, size, iron oxidation state, functionalization, and concentration is crucial for IONPs’ effectiveness. In addition to PTT, IONPs enhance other cancer treatment modalities. They improve tumor oxygenation, enhancing the efficacy of radiotherapy and photodynamic therapy. IONPs can also trigger ferroptosis, a programmed cell death pathway mediated by iron-dependent lipid peroxidation. Their magneto-mechanical effect allows them to exert a mechanical force on cancer cells to destroy tumors, minimizing the damage to healthy tissue. This review outlines strategies for the management of the photothermal performance and PTT efficiency with iron oxide nanoparticles, as well as synergies with other cancer therapies. Full article
(This article belongs to the Special Issue Nanoparticles for Cancer Diagnosis and Treatment)
Show Figures

Figure 1

Back to TopTop